anaesthetic & critical care studies summaries

---

Protocol v3.0 23/08/2023
​Rotherham Principal Investigator: Professor Anil Hormis
​Research team member: Dr Katie Webb

research topic:

Aspirin after hospitalisation with pneumonia to prevent cardiovascular events. 

trial groups:

Intervention: 7 days 150mg aspirin, followed by 84 days 75mg aspirin. 
Control: Usual care

inclusion criteria:

• Aged ≥ 50 years
  
• Symptoms and signs of acute lower respiratory tract infection
  
• Radiographic changes in keeping with infection on chest radiograph,CT scan or lung ultrasound scan

exclusion criteria:

Participants may not enter the study (i.e. may not be randomised) if ANY of the following apply: 

• already taking regular prescribed anti-platelet medication,including aspirin,clopidogrel,cangrelor,selexipag,cilostazol,dipyridamole,prasugrel,ticagrelor,abciximab,eptifibatide,tirofiban,epoprostenol,iloprost;
• a known allergy, previous important adverse reaction, or contraindication to aspirin;
• high risk of excessive bleeding (e.g. large trauma or haemorrhage or urgent need for major surgery or uncorrectable coagulopathy) in the opinion of the treating physician;
• hospital acquired pneumonia, defined as related to an inpatient hospital stay within the last 10 days or acquired at least 48 hours after current admission;
• unlikely to tolerate/adhere to medication regimen;
• Prisoners/pregnancy/life expectancy < 3 months due to pre-existing condition (e.g. terminal malignancy)
• presentation more likely due to acute COVID-19 pneumonitis in the opinion of the treating physician i.e. newly positive PCR or similar antigen test for COVID-19

consent:

Formal consent is required for ASPECT trial enrolment/randomisation.
If you think your patient is in any way eligible, please contact the research team who will review the full inclusion/exclusion criteria and approach for consent.